Compared to Estimates, Teleflex (TFX) Q4 Earnings: A Look at Key Metrics

Teleflex (TFX) reported $795.41 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 2.8%. EPS of $3.89 for the same period compares to $3.38 a year ago.The reported revenue represents a surprise of -2.23% over the Zacks Consensus Estimate of $813.53 million. With the consensus EPS estimate being $3.86, the EPS surprise was +0.78%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Teleflex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenues- Americas: $540.80 million versus $468.16 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +20% change. Geographic Revenues- Asia: $93.60 million compared to the $99.25 million average estimate based on eight analysts. Geographic Revenues- EMEA: $161 million versus the eight-analyst average estimate of $164.54 million. Net Revenues- Interventional: $160.40 million compared to the $158.48 million average estimate based on 12 analysts. The reported number represents a change of +18.3% year over year. Net Revenues- Interventional Urology: $84.90 million versus $92.23 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a -8.7% change. Revenues- OEM (Original Equipment Manufacturer and Development Services): $85.40 million versus the 12-analyst average estimate of $84.13 million. The reported number represents a year-over-year change of +3.4%. Net Revenues- Vascular Access: $189.30 million versus $201.17 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a +1.4% change. Net Revenues- Anesthesia: $95.30 million versus $104.17 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a -3% change. Net Revenues- Other: $58.20 million versus the 12-analyst average estimate of $55.18 million. The reported number represents a year-over-year change of -14.7%. Net Revenues- Surgical: $121.90 million versus $118.18 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a +11.2% change. View all Key Company Metrics for Teleflex here>>>Shares of Teleflex have returned -1.6% over the past month versus the Zacks S&P 500 composite's -2.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teleflex Incorporated (TFX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks